India, May 14 -- Shares of Septerna, Inc. (SEPN) soared over 50% on Wednesday morning after pharma giant Novo Nordisk (NVO) reached a $2.2 billion deal with Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.
SEPN is currently trading at $10.25, up $3.52 or 52.36%, on a huge volume of 20 million shares, above average volume of 0.5 million, on the Nasdaq. The stock opened its trading at $10.82 after closing Tuesday at $6.73. The stock has traded between $4.17 and $28.99 in the past 52-week period.
Septerna and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases...